... SAN FRANCISCO Nov. 7 /- Epiphany Biosciences announc... The initiation of this dose-finding study is an important milestone i... There are roughly one million cases of herpes zoster in the UnitedSt... Advancing a therapy that is conducive to better compliance is sorely...

SAN FRANCISCO, Nov. 7 /PRNewswire/ -- Epiphany Biosciences announced
today that the first patient was enrolled in a Phase 2b clinical trial with
valomaciclovir (EPB-348) for the treatment of herpes zoster, also known as
shingles. Valomaciclovir is a highly potent anti-viral with enhanced
delivery and bioavailability.

"The initiation of this dose-finding study is an important milestone in
our development of valomaciclovir," said Fred Volinsky, MD, Chief Executive
Officer. "Shingles, especially in the elderly population, can pose a
serious threat to quality of life. Despite the approval of the adult zoster
vaccine, we believe that the potential market for effective zoster
medications will double in size based on the published vaccine efficacy
rates and the aging of the baby boomers."

"There are roughly one million cases of herpes zoster in the United
States annually and current therapy requires multiple dosing, anywhere from
three to five times a day. These dosing schedules can be problematic for
patient populations who are already taking multiple medications for other
co-morbid conditions," stated Brian Murphy, MD, Chief Medical Officer.
"This clinical trial is designed to examine the safety and efficacy of
once-daily valomaciclovir against an active comparator, three times daily
valacyclovir, and is adequately powered to assess a number of pivotal
outcomes."

"Advancing a therapy that is conducive to better compliance is sorely
needed in this therapeutic space," noted Dr. Stephen Tyring, Professor of
Medicine at the University of Texas Health Science Center in Houston and
principal investigator for the study. "In light of the improved
pharmacodynamic profile offered by this drug, it is important to study it
in larger, diverse populations that can be affected by herpes zoster."

The number of elderly patients at-risk for this disease is expected to
increase dramatically over the next decade as the world population ages.
"While we are working to advance valomaciclovir to become the next global
brand for the management of shingles, we are pleased that this compound
also exhibits activity both in vitro and in vivo against other types of
viruses. We plan to explore these potential broad therapeutic possibilities
given the spectrum of this anti-viral profile," said Dr. Volinsky.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for viral
disease. Epiphany has formed a world-class virology team that includes two
Lasker Award winners. Epiphany is located in San Francisco, CA. Additional
information on Epiphany Biosciences may be obtained at the company website,
http://www.epiphanybio.com, or by contacting company representatives at
415.765.7193.

(Date:10/2/2017)... AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...

(Date:9/27/2017)... Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche. To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...

(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain medications ... from Austin, Texas, has identified a solution. , She developed a prototype for MOTION ... As such, it eliminates the need to turn on a light when taking medication ...

(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...

(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...

(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...

(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...